Drugs / YTTRIUM Y 90 EPRATUZUMAB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00421395 | Aug 2002 → Oct 2007 | B-cell non-Hodgkin lymphoma | Gilead Sciences | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YTTRIUM Y 90 EPRATUZUMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108817 ↗ |
| Known as | 90Y-hLL2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00421395 ↗ |
| Known as | Epratuzumab (y 90) | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108817 ↗ |
| Known as | S9S0Y-HLL2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108817 ↗ |
| Modality | Monoclonal antibody | “intact monoclonal antibody IgG” NCT00421395 ↗ |
| Target | CD22 | “CD22 binding agent” CHEMBL2108817 ↗ |